Neuromodulation : journal of the International Neuromodulation Society
-
Objectives. To perform a preliminary cost-utility and cost-benefit of deep brain stimulation (DBS) in the treatment of dystonia, Materials and Methods. We conducted a prospective study of 26 patients undergoing DBS for the treatment of dystonia. We performed a cost-utility analysis using the Euroquol (EQ-5D) questionnaire. ⋯ There was an overall gain of 0.94 quality-adjusted life-years (QALY) with a cost of £33,980 per QALY. Conclusions. DBS for dystonia, while an expensive treatment, compares favorably to therapies that are commonly used for other conditions.
-
Objective. The purpose of this study was to investigate the utility of a 7-day percutaneous spinal cord stimulator trial using a 7-day diary to measure outcomes during the trial and at long-term follow-up. Materials and Method. Diaries completed prior to and during the trial were analyzed, as was a follow-up questionnaire. Trial and follow-up data were compared using nonparametric statistics and descriptive analyses. ⋯ Conclusion. Patients who underwent a 7-day percutaneous trial, had a positive trial and received permanent implantation fared well long-term. The 7-day diary did not result in a superior method of determining responders vs. nonresponders at long-term follow-up. More research is needed to determine whether different quantitative measures would predict long-term outcome.
-
Introduction. Intrathecal octreotide has been considered an alternative to opioids in chronic infusion for pain. Octreotide is an analog of the growth hormone sandostatin. Previous work has shown the drug to be efficacious in cancer patients who had failed intrathecal opioids. ⋯ The Saint Francis Hospital IRB and FDA approved the ongoing use of intrathecal octreotide for research. Conclusions. Intrathecal octreotide, at doses as high as 20 µg/hr, appeared to be as safe as saline when given as a continuous intrathecal infusion. Further work is needed on dose-range analysis and efficacy.